UPBUpstream Bio Inc. Common Stock

6.970USD-7.25%Mkt Cap: 381.75M $P/E:

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of sev…

Key Statistics

Company
Market Cap381.75M $
Enterprise Value114.83M $
Revenue (TTM)3.16M $
Gross Profit3.16M $
Net Income (TTM)-143.44M $
Revenue/Share0.0580 USD
Last Price6.970 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees75
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-2.34
PEG
EV/EBITDA-0.68
EV/Revenue36.36
P/S118.80
P/B1.38
EPS (TTM)-2.62
EPS (Forward)-2.93
52W Range
5.8504% of range33.68
52W High33.68 USD
52W Low5.850 USD
Profitability
Gross Margin100.00%
Oper. Margin-5480.98%
EBITDA Margin0.00%
Profit Margin-5026.03%
ROE-42.22%
ROA-40.55%
Growth
Revenue Growth-17.50%
Earnings Growth
Cash Flow & Leverage
Operating CF-133.28M $
CapEx (TTM)165.00K $
FCF Margin-2742.75%
FCF Yield-22.69%
Net Debt-260.35M $
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.00
Current Ratio27.99
Quick Ratio26.38
Book Value/Sh4.947 USD
Cash/Share4.771 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.50 USD
Upside (mean)+380.6%
Target Range9.000 USD75.00 USD
$9.000+380.6% to mean$75.00
# Analysts8
Ownership
Shares Out.54.77M
Float42.81M
Insiders14.78%
Institutions92.52%
Short Interest
Short Ratio7.7d
Short % Float10.24%
Short % Out.6.66%
Shares Short3.65M
Short (prev mo.)4.11M
Technical
SMA 506.834 (+2.0%)
SMA 20014.86 (-53.1%)
Beta
S&P 52W Chg18.16%
Avg Vol (30d)549.18K
Avg Vol (10d)630.26K
Technical Indicators
RSI (14)49.8
MACD0.0571
MACD Signal-0.0016
MACD Hist.+0.0588
BB Upper7.552 USD
BB Middle6.801 USD
BB Lower6.050 USD
BB Width22.09%
ATR (14)0.4232 USD
Vol Ratio (20d)0.69x